|
Characteristica
|
Intervention
|
Control
|
Inter-action
|
|---|
| |
Baseline
|
Follow-up
|
OR (95% CI)**
|
p-value**
|
Baseline
|
Follow-up
|
OR (95% CI)**
|
p-value**
|
p-value**
|
|---|
|
Women
|
|
CVD patients
|
|
Statin prescribed
|
39.1 (382/978)
|
54.6 (574/1051)
|
1.86 (1.56–2.22)
|
< 0.001
|
24.3 (78/321)
|
33.0 (107/324)
|
1.53 (1.08–2.16)
|
0.016
|
0.314
|
|
HT drug prescribed
|
90.3 (883/978)
|
93.1 (978/1051)
|
1.43 (1.04–1.96)
|
0.029
|
81.0 (260/321)
|
86.1 (279/324)
|
1.43 (0.94–2.19)
|
0.096
|
0.959
|
|
TC documented
|
33.5 (328/978)
|
60.2 (633/1051)
|
3.07 (2.56–3.69)
|
< 0.001
|
24.3 (78/321)
|
28.1 (91/324)
|
1.25 (0.87–1.78)
|
0.224
|
< 0.001
|
|
TC at normal range
|
30.5 (100/328)
|
34.4 (218/633)
|
1.20 (0.90–1.60)
|
0.215
|
29.5 (23/78)
|
48.4 (44/91)
|
2.18 (1.15–4.15)
|
0.017
|
0.078
|
|
HT patients
|
|
HT drug prescribed
|
93.5 (1030/1102)
|
96.0 (1127/1174)
|
1.67 (1.15–2.44)
|
0.008
|
85.2 (339/398)
|
89.7 (366/408)
|
1.46 (0.95–2.23)
|
0.084
|
0.710
|
|
BP control
|
15.2 (134/882)
|
12.1 (120/995)
|
0.77 (0.59–1.01)
|
0.055
|
10.4 (33/316)
|
13.2 (46/348)
|
1.32 (0.82–2.12)
|
0.255
|
0.054
|
|
DM patients
|
|
HbA1c documented
|
21.4 (49/229)
|
27.1 (71/262)
|
1.44 (0.95–2.20)
|
0.089
|
9.3 (5/54)
|
10.7 (9/84)
|
1.15 (0.36–3.65)
|
0.817
|
0.720
|
|
FG documented
|
91.7 (210/229)
|
92.4 (242/262)
|
1.16 (0.60–2.25)
|
0.656
|
77.8 (42/54)
|
89.3 (75/84)
|
2.37 (0.92–6.12)
|
0.076
|
0.231
|
|
TC documented
|
41.9 (96/229)
|
64.1 (168/262)
|
2.48 (1.72–3.57)
|
< 0.001
|
29.6 (16/54)
|
34.5 (29/84)
|
1.24 (0.59–2.60)
|
0.563
|
0.101
|
|
Statin prescribed
|
49.8 (114/229)
|
59.2 (155/262)
|
1.45 (1.01–2.08)
|
0.043
|
24.1 (13/54)
|
32.1 (27/84)
|
1.52 (0.70–3.31)
|
0.291
|
0.924
|
|
BP control
|
2.7 (6/226)
|
4.7 (12/258)
|
1.89 (0.70–5.14)
|
0.212
|
9.8 (5/51)
|
6.0 (5/84)
|
0.58 (0.16–2.12)
|
0.412
|
0.168
|
|
FG control
|
35.2 (74/210)
|
40.5 (98/242)
|
1.20 (0.82–1.77)
|
0.352
|
47.6 (20/42)
|
44.0 (33/75)
|
0.89 (0.41–1.90)
|
0.755
|
0.484
|
|
TC at normal range
|
29.2 (28/96)
|
30.4 (51/168)
|
1.01 (0.58–1.76)
|
0.979
|
12.5 (2/16)
|
37.9 (11/29)
|
4.36 (0.82–23.21)
|
0.085
|
0.089
|
|
Men
|
|
CVD patients
|
|
Statin prescribed
|
47.9 (395/825)
|
56.3 (502/891)
|
1.39 (1.15–1.69)
|
0.001
|
30.7 (79/257)
|
43.0 (120/279)
|
1.66 (1.16–2.37)
|
0.006
|
0.390
|
|
HT drug prescribed
|
87.0 (718/825)
|
90.1 (803/891)
|
1.36 (1.01–1.83)
|
0.046
|
76.3 (196/257)
|
84.9 (237/279)
|
1.68 (1.08–2.61)
|
0.020
|
0.364
|
|
TC documented
|
35.8 (295/825)
|
60.8 (542/891)
|
2.85 (2.34–3.47)
|
< 0.001
|
25.2 (65/257)
|
33.7 (94/279)
|
1.65 (1.12–2.42)
|
0.011
|
0.006
|
|
TC at normal range
|
41.0 (121/295)
|
43.9 (238/542)
|
1.12 (0.84–1.50)
|
0.435
|
49.2 (32/65)
|
50.0 (47/94)
|
1.01 (0.54–1.91)
|
0.969
|
0.793
|
|
HT patients
|
|
HT drug prescribed
|
91.6 (846/924)
|
94.5 (924/978)
|
1.56 (1.09–2.24)
|
0.015
|
82.9 (271/327)
|
89.2 (313/351)
|
1.58 (1.01–2.47)
|
0.046
|
0.863
|
|
BP control
|
14.8 (104/705)
|
15.6 (126/806)
|
1.08 (0.82–1.44)
|
0.578
|
9.6 (24/250)
|
13.8 (42/305)
|
1.53 (0.89–2.60)
|
0.122
|
0.254
|
|
DM patients
|
|
HbA1c documented
|
21.2 (33/156)
|
27.1 (52/192)
|
1.40 (0.84–2.31)
|
0.194
|
9.8 (5/51)
|
15.9 (11/69)
|
2.13 (0.67–6.80)
|
0.203
|
0.565
|
|
FG documented
|
83.3 (130/156)
|
91.1 (175/192)
|
2.06 (1.07–3.95)
|
0.030
|
86.3 (44/51)
|
79.7 (55/69)
|
0.65 (0.24–1.78)
|
0.402
|
0.055
|
|
TC documented
|
46.2 (72/156)
|
70.3 (135/192)
|
2.78 (1.78–4.32)
|
< 0.001
|
49.0 (25/51)
|
42.0 (29/69)
|
0.82 (0.39–1.73)
|
0.607
|
0.004
|
|
Statin prescribed
|
57.7 (90/156)
|
62.5 (120/192)
|
1.22 (0.79–1.89)
|
0.361
|
31.4 (16/51)
|
43.5 (30/69)
|
1.62 (0.75–3.48)
|
0.222
|
0.578
|
|
BP control
|
6.5 (10/153)
|
7.8 (15/192)
|
1.22 (0.53–2.80)
|
0.647
|
2.1 (1/47)
|
6.0 (4/67)
|
3.36 (0.35–32.02)
|
0.292
|
0.521
|
|
FG control
|
38.5 (50/130)
|
38.9 (68/175)
|
1.02 (0.64–1.64)
|
0.925
|
47.7 (21/44)
|
40.0 (22/55)
|
0.76 (0.34–1.69)
|
0.496
|
0.425
|
|
TC at normal range
|
41.7 (30/72)
|
34.1 (46/135)
|
0.72 (0.40–1.31)
|
0.283
|
36.0 (9/25)
|
27.6 (8/29)
|
0.62 (0.19–2.00)
|
0.420
|
0.873
|
- Abbreviations: CVD cardiovascular disease; HT hypertension; TC total cholesterol; BP blood pressure; DM diabetes mellitus; HbA1c glycated haemoglobin; FG fasting glucose; OR odds ratio; CI confidence interval
- aTC documented = Proportion of patients in the defined patient group with at least one documented total cholesterol measurement; Statin prescribed = Proportion of patients in the defined patient groups with stating prescribed; HT drug prescribed = Proportion of patients in the defined patient group prescribed blood pressure lowering drug; TC at normal range = Proportion of patients with cardiovascular disease whose last total cholesterol measurement was < 5 mmol/l; HT patients with BP control = Proportion of confirmed hypertensive patients whose last two blood pressure measurements were controlled (SBP < 140 mmHg and DBP < 90 mmHg), of which at least the most recent one during the last 12 months; DM patients with BP control = Proportion of diabetic patients whose last recorded blood pressure measurement was at normal range (systolic blood pressure < 130 mmHg and diastolic blood pressure < 80 mmHg); DM patients with FG control = Proportion of patients whose last fasting glucose measurement was < 7 mmol/l
- ** Age adjusted
